Reviews/Statins/Statins reduce MACE and mortality in patients with established cardiovascular disease
· ST-SEC-01 · v2
In people who already have heart disease, the evidence here points the same way: those taking statins have fewer heart attacks, strokes and related events, and in one large study fewer deaths too. The strongest records are a nationwide study of bypass-surgery patients [7] and a study of older patients who stopped versus continued statins [8], plus a trial in post-heart-attack patients [1]. The catch is that the two biggest studies simply observe who happened to take statins rather than assigning them at random, so the people on statins may differ from those not on them in ways that flatter the drug. The one randomised trial in this set tested a three-drug combination pill [1], so it cannot show the statin alone did the work. The death benefit in particular leans heavily on a single study [7]. The panel therefore treated the direction as consistent and population-appropriate but did not place it at the top tier.
In genuine secondary-prevention populations, ongoing statin use after bypass surgery was associated with lower MACE (aHR 0.56), all-cause mortality (aHR 0.53) and cardiovascular death (aHR 0.54) in 35,193 patients [7]. In 39,955 older secondary-prevention patients, discontinuing statins was associated with higher MACE (adjusted sub-hazard ratio 1.28) relative to continuing [8]. A randomised post-myocardial-infarction trial found a statin-containing polypill lowered MACE versus usual care (HR 0.76) [1]. Within an acute coronary syndrome trial, patients on no statin had the highest placebo-arm MACE incidence at 26.0% [3]. The events-reduction signal is consistent in direction across all four records. The contested point: The division is causal attribution, not direction: the two largest records [7, 8] are observational and open to confounding by indication and the healthy-adherer effect, while the only randomised evidence [1] tests a polypill and cannot isolate the statin. Within that, the mortality limb is thinner than the MACE limb, resting chiefly on [7].
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Statins, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only RCT in the eligible corpus [1] tests a polypill (aspirin + ramipril + atorvastatin), so its MACE reduction cannot be attributed to the statin; the corpus contains no randomised statin-vs-placebo comparison in secondary prevention.
The direct secondary-prevention evidence [7] and [8] is observational and subject to confounding by indication and the healthy-adherer effect; statin users and continuers differ systematically from non-users and discontinuers, and [7] reports association, not causation.
Where it remains uncertain. The mortality limb rests chiefly on one observational study [7]; the sole RCT [1] tests a three-drug polypill and shows no isolated statin mortality benefit, and no randomised statin-versus-placebo secondary-prevention trial is present.
Aleatory
The post-MI polypill effect rests on modest event counts (118 vs 156 primary events) with a confidence interval approaching the null (HR 0.76; 0.60-0.96) [1].
Epistemic
The corpus holds no randomised statin-versus-placebo secondary-prevention comparison; the only RCT [1] is a polypill, so a key piece of knowledge is simply missing from the available evidence.
Inferential
The direct records [7, 8] compare users with non-users and continuers with discontinuers who differ systematically, so the association may overstate the drug's effect.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Randomised post-MI evidence that a statin-containing regimen reduces MACE, though the statin effect is not isolable from aspirin and ramipril.
“A primary-outcome event occurred in 118 of 1237 patients (9.5%) in the polypill group and in 156 of 1229 (12.7%) in the usual-care group (hazard ratio, 0.76; 95% confidence interval [CI], 0.60 to 0.96; P = 0.02).”
Panel auditInternal validity: high · scope of inference: Patients within 6 months of myocardial infarction receiving a polypill strategy versus usual care.Key limitations: statin effect not separable from aspirin and ACE inhibitor · open comparison against usual care · adherence confound (adherence higher in polypill group)
Indirect within-trial observation in ACS patients consistent with higher MACE in the absence of statin therapy; confounded, non-randomised.
“With placebo, the incidence of major adverse cardiovascular events was highest in the no statin subgroup (10.8%, 10.7% and 26.0% respectively).”
Panel auditInternal validity: high · scope of inference: Post-ACS patients with dyslipidaemia on varying statin intensity, assessing an added PCSK9 inhibitor.Key limitations: statin comparison is observational subgroup, not randomized · no-statin subgroup selected by intolerance · intervention under test is alirocumab
Direct secondary-prevention (post-CABG) evidence covering both the MACE and mortality limbs of the claim in 35,193 patients.
“Ongoing statin treatment was associated with markedly reduced risk of MACE (adjusted hazard ratio [aHR], 0.56 [95% CI, 0.53-0.59]), all-cause mortality (aHR, 0.53 [95% CI, 0.50-0.56]), cardiovascular death (aHR, 0.54 [95% CI, 0.50-0.59])”
Panel auditInternal validity: medium · scope of inference: Patients who underwent first-time isolated CABG in Sweden and survived at least 6 months.Key limitations: observational, not randomized · confounding by indication / healthy-adherer bias · post-CABG only, may not generalise to all established CVD
3 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent, large, population-appropriate effects support the claim, but reliance on observational data and a non-isolating RCT caps confidence below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No isolating randomised statin trial in secondary prevention. Causal attribution for both MACE and mortality depends on a randomised statin-versus-placebo comparison, which the corpus lacks; the sole RCT is a polypill [1]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised placebo-controlled statin trial (or an individual-participant meta-analysis of such trials) restricted to established-CVD patients reporting MACE and all-cause mortality.
Open question: In established cardiovascular disease, does a statin alone (versus placebo) reduce MACE and all-cause mortality? Why it is still open: The corpus contains no randomised statin-versus-placebo secondary-prevention trial; the only RCT [1] tests a three-drug polypill.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19